Five TNFα inhibitors are currently available for patient care in Europe: adalimumab and infliximab are, among others, approved for RD, IBD, and psoriasis, etanercept and certolizumab pegol are approved for RD and psoriasis and golimumab is approved for RD and IBD.1, 2, 3, 4, 5. Here, TNF is linked to inflammatory bowel disease.